Clinical Trial Update: A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating pembrolizumab combined with standard treatment in recurrent platinum-resistant ovarian cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Cedars-Sinai Medical Center | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-17